• Vivesto flagged newly reported topline results from two Paccal Vet studies for presentation at the Veterinary Cancer Society conference on Sept. 24.
• Dog pilot study in splenic hemangiosarcoma showed supportive survival and safety outcomes, reinforcing the case to move into a pivotal trial.
• Cat dose-escalation study indicated tolerability with early signs of single-agent anti-tumor activity; final results are expected in Q4 2026.
• Data were previously presented as topline results in September 2026; the conference posters provide an external forum for scientific review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivesto AB published the original content used to generate this news brief on September 24, 2026, and is solely responsible for the information contained therein.